#1 Clinical Trials Search in Europe

Mbs2320

Mbs2320 is being studied in clinical trials for people with idiopathic pulmonary fibrosis (IPF), a long-term lung disease that causes scarring. The trial data focus on whether Mbs2320 can improve or slow loss of lung function, and they also look at safety and treatment effects in adults with IPF.

Table of Contents

Trial overview

The available clinical trial studied Mbs2320 in people with idiopathic pulmonary fibrosis (IPF), a disease that causes scarring in the lungs and can make breathing harder.[1]

This was an interventional study, which means researchers gave a study treatment and compared results between groups.[1]

Who was studied

The study focused on participants with IPF.[1]

The source data do not list extra entry rules such as age range, disease stage, or other medical requirements, so those details are not available here.

A total of 306 participants were enrolled.[1]

Treatment and comparison

Participants received daily oral Mbs2320 or placebo, which is a look-alike treatment with no active study drug.[1]

The trial compared Mbs2320 capsules 40 mg with placebo capsules that matched the study drug.[1]

The brief study summary says the treatment period lasted 12 weeks.[1]

What the trial measured

The main outcome was the change from baseline in forced vital capacity (FVC) compared with placebo up to Week 12 or until treatment was stopped.[1]

FVC is the amount of air a person can blow out after taking the deepest breath possible, so it is an important measure of lung function.

The study summary also says the trial aimed to evaluate the effect of daily oral dosing of Mbs2320 on the absolute change in FVC measured in milliliters.[1]

Trial design and phase

The study was a Phase 2 trial.[1]

Phase 2 studies are usually done after early safety testing and are designed to learn more about whether a treatment may help the condition being studied.

The trial status is listed as Completed.[1]

What the results section means for patients

From the source data, the main question in this trial was whether Mbs2320 could change lung function in people with IPF compared with placebo.[1]

The trial does not provide result numbers in the source material, so this article only summarizes the study design, target group, and outcome being measured.

Because the trial was completed, the study question has been tested in a real patient group, but the provided data do not include the final findings.

Trial ID Phase Condition studied Status Enrollment
2023-504418-30-00 Phase 2 Idiopathic Pulmonary Fibrosis Completed 306

FAQ

  • What is Mbs2320 being studied for? The trial is studying Mbs2320 in idiopathic pulmonary fibrosis (IPF). The main goal is to see whether it changes lung function compared with placebo.
  • Who could take part in the trial? The trial included participants with IPF. The source data do not give more detailed entry rules, such as age limits or other health requirements.
  • What phase was the Mbs2320 trial? The study was a Phase 2 trial. Phase 2 trials usually look more closely at whether a treatment may work and continue to monitor safety.
  • What was the main outcome measured? The main outcome was the change from baseline in forced vital capacity, or FVC, compared with placebo. FVC is the amount of air a person can force out of the lungs.
  • Was the trial completed? Yes. The trial status in the source data is Completed. It enrolled 306 participants.

Ongoing Clinical Trials on Mbs2320

  • Study on the Effects of MBS2320 for Patients with Idiopathic Pulmonary Fibrosis (IPF)

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Hungary Italy Spain

Glossary

  • Idiopathic Pulmonary Fibrosis (IPF): A long-term lung disease that causes scarring in the lungs. 'Idiopathic' means the cause is not known.
  • Placebo: A look-alike treatment with no active study drug. It is used to compare results fairly.
  • Phase 2: A mid-stage clinical trial that looks at whether a treatment may work and continues to check safety.
  • Interventional study: A study where researchers assign a treatment to participants to see what happens.
  • Forced Vital Capacity (FVC): The amount of air a person can blow out after taking the deepest breath possible. It is a common measure of lung function.
  • Baseline: The first measurement taken before treatment starts. It is used as a starting point for comparison.
  • Primary outcome: The main result a trial is designed to measure.
  • Enrollment: The number of people who joined the study.
  • Discontinuation: Stopping the study treatment before the planned end.

References

  1. https://clinicaltrials.gov/study/2023-504418-30-00